MOXIFLOXACIN HYDROCHLORIDE

Post-LOE

moxifloxacin hydrochloride

Teva

ANDAORALTABLET

Approved

Aug 2015

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

MOXIFLOXACIN HYDROCHLORIDE (moxifloxacin hydrochloride) by Teva is 12. Approved for haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus and 21 more indications. First approved in 2015.

Drug data last refreshed 18h ago

Mechanism of Action

12.1 Mechanism of Action Moxifloxacin hydrochloride is a member of the fluoroquinolone class of antibacterial agents [see ] . 12.2 Pharmacodynamics Photosensitivity Potential A study of the skin response to ultraviolet (UVA and UVB) and visible radiation conducted in 32 healthy volunteers (8 per…

Worked on MOXIFLOXACIN HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

MOXIFLOXACIN HYDROCHLORIDE

Mechanism of Action

Indications (19)

Clinical Trials (1)